Elixinol Wellness Limited (EXL.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 15 | 9 | 7 | 8 | 15 | 16 | 15 | - |
| Operating profit | AUD m | -5 | -3 | ||||||
| Net profit | AUD m | -105 | -17 | -11 | -8 | -2 | -5 | -3 | - |
| EPS reported | AUD | -0.02 | -0.01 | ||||||
| Operating cashflow per share | AUD | -0.01 | -0.01 | ||||||
| Capex per share | AUD | 0.00 | 0.00 | ||||||
| FCF per share | AUD | -0.01 | -0.01 | ||||||
| Free cash flow | AUD m | -3 | -3 | ||||||
| Net debt | AUD m | 2 | 3 | ||||||
| Book value equity | AUD m | 7 | 6 | ||||||
| Book value per share | AUD | 0.03 | 0.02 | ||||||
| Number of shares | m | 256.21 | 413.99 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.31 | 0.36 | ||||||
| P/S LTM | x | 0.15 | 0.15 | ||||||
| P/FCF LTM | x | -0.70 | -0.88 | ||||||
| EV/EBITDA LTM | x | -1.13 | -2.37 | ||||||
| EV/Sales LTM | x | 0.30 | 0.23 | ||||||
| Earnings Yield LTM | % | -2.39% | -2.87% | ||||||
| FCF Yield | % | -142.20% | -113.45% | ||||||
| Quality | |||||||||
| ROE | % | -73.81% | -76.30% | ||||||
| ROIC | % | -35.63% | -31.81% | ||||||
| Operating margin | % | -32.10% | -28.62% | ||||||
| Gross margin | % | +4.85% | +20.00% | ||||||
| FCF/Sales | % | -21.15% | -21.12% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +3.64% | +0.66% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.88 | -0.65 | ||||||
| Net Debt/EBITDA | x | -0.56 | -0.51 | ||||||
| EBIT/Net interest | x | -10.20 | -9.10 | ||||||
| Net debt/market cap | % | +1.46% | +2.57% | ||||||
| Net debt/Equity | x | 0.26 | 0.48 | ||||||
| Gross debt/equity | x | 0.50 | 0.63 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Elixinol Wellness Limited (EXL.AX)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free